Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

The role of checkpoints in the treatment of GBM JOURNAL OF NEURO-ONCOLOGY Kim, J. E., Lim, M. 2015; 123 (3): 413–23

Abstract

Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

View details for DOI 10.1007/s11060-015-1747-8

View details for Web of Science ID 000358160000011

View details for PubMedID 25749875

View details for PubMedCentralID PMC4750481